Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$35.97

16.06 (80.66%)

10:39
08/13/19
08/13
10:39
08/13/19
10:39

Deciphera price target raised to $66 from $44 at Guggenheim

Guggenheim analyst Michael Schmidt raised his price target on shares of Deciphera to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study.

  • 13

    Aug

DCPH Deciphera
$35.97

16.06 (80.66%)

06/03/19
PIPR
06/03/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera price target raised to $55 from $50 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Deciphera Pharmaceuticals (DCPH) to $55 from $50 after hosting investor meetings with management and reviewing competitor Blueprint Medicines' (BPMC) avapritinib update over the weekend. Given the "significant" valuation-gap between the two companies, driven by misperceptions around their respective KIT inhibitors, new money investment into Deciphera "right here makes a lot of sense," Raymond tells investors in a research note. He keeps an Overweight rating on the shares.
06/10/19
PIPR
06/10/19
NO CHANGE
Target $55
PIPR
Overweight
Piper Jaffray says a buyer of Deciphera after DCC-3116 added to pipeline
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $55 price target on Deciphera following the disclosure of the company's newest preclinical candidate, DCC-3116, an ULK kinase inhibitor important in autophagy initiation. In a research note to investors, Raymond says that given recent advances in KRAS targeting, this target's complementary effects make it an "intriguing" combination agent with the myriad agents approved and in development, adding that he remains a buyer.
07/18/19
DBAB
07/18/19
INITIATION
Target $42
DBAB
Buy
Deciphera initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Deciphera with a Buy rating and $42 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
08/13/19
PIPR
08/13/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera Phase 3 Invictus study a 'best-case' scenario, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views this morning's Phase 3 Invictus study results from Deciphera Pharmaceuticals as a "best-case" scenario. A 27.6 week progression free survival measure was better than the un-adjudicated Phase 1 experience of 24 weeks, and was also statistically significant improved versus placebo, Raymond tells investors in a research note. While some may quibble with a non-statistically significant overall response rate, this "misses the broader point, which is that ripretinib is now not just approvable, but in our view very likely the best-in-class KIT inhibitor" in gastrointestinal stromal tumors, says Raymond. He expects Deciphera shares to "rally sharply" today and keeps an Overweight rating on the name with a $55 price target. The stock in premarket trading is up 122%, or $24.40, to $44.35.

TODAY'S FREE FLY STORIES

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Total Amount data reported »

30-Yr TIPS Auction Total…

NTRA

Natera

$30.66

0.25 (0.82%)

13:18
08/22/19
08/22
13:18
08/22/19
13:18
Hot Stocks
Natera reports 'positive' local coverage determination issued by Palmetto MolDX »

Natera announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/22/19
08/22
13:17
08/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/22/19
08/22
13:16
08/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
08/22/19
08/22
13:15
08/22/19
13:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

NTRA

Natera

$30.53

0.12 (0.39%)

13:13
08/22/19
08/22
13:13
08/22/19
13:13
Recommendations
Natera analyst commentary  »

Piper says Natera gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

13:10
08/22/19
08/22
13:10
08/22/19
13:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD peaked…

AMGN

Amgen

$204.16

0.32 (0.16%)

13:06
08/22/19
08/22
13:06
08/22/19
13:06
Hot Stocks
Amgen granted orphan designation for multiple myeloma treatment »

Amgen was granted orphan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

ZIOP

Ziopharm

$5.09

-0.06 (-1.17%)

13:05
08/22/19
08/22
13:05
08/22/19
13:05
Options
Ziopharm call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

SNY

Sanofi

$42.69

-0.48 (-1.11%)

13:04
08/22/19
08/22
13:04
08/22/19
13:04
Hot Stocks
Sanofi treatment of systemic sclerosis granted orphan designation »

Sanofi U.S. Service was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 02

    Oct

WFC

Wells Fargo

$45.62

0.63 (1.40%)

13:03
08/22/19
08/22
13:03
08/22/19
13:03
Periodicals
Wells Fargo to pay $6.5M to Navajo Nation to settle account suit, Reuters says »

Wells Fargo intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Oct

  • 15

    Oct

  • 27

    Oct

ILMN

Illumina

$288.00

-2.5 (-0.86%)

13:02
08/22/19
08/22
13:02
08/22/19
13:02
Hot Stocks
Illumina granted orphan designation neuroblastoma management diagnostic »

Illumina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

OSTK

Overstock.com

$21.84

2.34 (12.00%)

12:49
08/22/19
08/22
12:49
08/22/19
12:49
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock.com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$21.40

1.9 (9.74%)

12:45
08/22/19
08/22
12:45
08/22/19
12:45
Options
Overstock com call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$203.13

-0.71 (-0.35%)

, ALXN

Alexion

$118.04

3.17 (2.76%)

12:43
08/22/19
08/22
12:43
08/22/19
12:43
Recommendations
Amgen, Alexion analyst commentary at Piper Jaffray »

Piper Jaffray says Amgen…

AMGN

Amgen

$203.13

-0.71 (-0.35%)

ALXN

Alexion

$118.04

3.17 (2.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

12:40
08/22/19
08/22
12:40
08/22/19
12:40
General news
Fed funds futures are lower after the hawkish comments »

Fed funds futures are…

ADM

Archer Daniels

$37.93

0.23 (0.61%)

, REGI

Renewable Energy

$11.27

0.42 (3.87%)

12:38
08/22/19
08/22
12:38
08/22/19
12:38
Periodicals
Trump to discuss biofuels with USDA, EPA officials, Reuters reports »

President Donald Trump is…

ADM

Archer Daniels

$37.93

0.23 (0.61%)

REGI

Renewable Energy

$11.27

0.42 (3.87%)

GPRE

Green Plains

$8.03

0.15 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

OSTK

Overstock.com

$19.54

0.04 (0.21%)

12:33
08/22/19
08/22
12:33
08/22/19
12:33
Hot Stocks
Byrne says Overstock's blockchain keiretsu will revolutionize the world »

In a letter to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSTK

Overstock.com

$19.54

0.04 (0.21%)

12:30
08/22/19
08/22
12:30
08/22/19
12:30
Hot Stocks
Breaking Hot Stocks news story on Overstock.com »

Overstock com trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.12

-0.28 (-0.10%)

, SPX

S&P 500

$0.00

(0.00%)

12:29
08/22/19
08/22
12:29
08/22/19
12:29
General News
Canada still against Russia's return to G8, Reuters says »

Canada's government…

SPY

SPDR S&P 500 ETF Trust

$292.12

-0.28 (-0.10%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$292.07

-0.335 (-0.11%)

, SPX

S&P 500

$0.00

(0.00%)

12:28
08/22/19
08/22
12:28
08/22/19
12:28
General News
Ukraine, EU rebuff Trump's suggestion of admitting Russia to G7, Reuters says »

Ukraine's President…

SPY

SPDR S&P 500 ETF Trust

$292.07

-0.335 (-0.11%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

-2.27 (-1.24%)

, SNAP

Snap

$16.24

0.1 (0.62%)

12:27
08/22/19
08/22
12:27
08/22/19
12:27
Periodicals
Gun sellers allegedly used Snapchat to sell illegal guns, Guardian says »

Darwin BondGraham, a…

FB

Facebook

$181.29

-2.27 (-1.24%)

SNAP

Snap

$16.24

0.1 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.